Looking for Ritonavir found 20 matches
|
Links Link to Drug Section  Link to document |
|
LSCMMG: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab (05.03)
|
|
LSCMMG: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab (05.03)
|
|
LSCMMG: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab (05.03)
|
|
MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (05.03.01)
|
|
MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (05.03.01)
|
|
MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (05.03.01)
|
|
MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (05.03.01)
|
|
MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (05.03.01)
|
|
MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (05.03.01)
|
|
MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (05.03.01)
|
|
MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (05.03.01)
|
|
MHRA: Nirmatrelvir, ritonavir (Paxlovid▼): be alert to the risk of drug interactions with ritonavir (05.03)
|
|
MHRA: Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels (05.03.01)
|
|
MHRA: Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels (05.03.01)
|
|
NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (05.03)
|
|
NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (05.03)
|
|
NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (05.03)
|
|
|
